S&P 500   4,244.38 (+0.81%)
DOW   33,586.05 (+0.83%)
QQQ   328.85 (+0.90%)
AAPL   170.15 (+0.54%)
MSFT   289.18 (+0.01%)
META   181.30 (+1.66%)
GOOGL   120.53 (+0.69%)
AMZN   143.27 (+0.41%)
TSLA   879.87 (-0.36%)
NVDA   184.99 (+2.22%)
NIO   21.74 (+8.43%)
BABA   96.91 (+4.85%)
AMD   101.82 (+2.80%)
MU   63.76 (+3.84%)
T   18.13 (+0.67%)
CGC   3.34 (+1.52%)
GE   78.78 (+2.13%)
F   15.73 (+1.48%)
DIS   120.52 (+7.20%)
AMC   25.41 (+7.35%)
PYPL   100.64 (+1.75%)
PFE   48.78 (-2.34%)
NFLX   249.34 (+2.14%)
S&P 500   4,244.38 (+0.81%)
DOW   33,586.05 (+0.83%)
QQQ   328.85 (+0.90%)
AAPL   170.15 (+0.54%)
MSFT   289.18 (+0.01%)
META   181.30 (+1.66%)
GOOGL   120.53 (+0.69%)
AMZN   143.27 (+0.41%)
TSLA   879.87 (-0.36%)
NVDA   184.99 (+2.22%)
NIO   21.74 (+8.43%)
BABA   96.91 (+4.85%)
AMD   101.82 (+2.80%)
MU   63.76 (+3.84%)
T   18.13 (+0.67%)
CGC   3.34 (+1.52%)
GE   78.78 (+2.13%)
F   15.73 (+1.48%)
DIS   120.52 (+7.20%)
AMC   25.41 (+7.35%)
PYPL   100.64 (+1.75%)
PFE   48.78 (-2.34%)
NFLX   249.34 (+2.14%)
S&P 500   4,244.38 (+0.81%)
DOW   33,586.05 (+0.83%)
QQQ   328.85 (+0.90%)
AAPL   170.15 (+0.54%)
MSFT   289.18 (+0.01%)
META   181.30 (+1.66%)
GOOGL   120.53 (+0.69%)
AMZN   143.27 (+0.41%)
TSLA   879.87 (-0.36%)
NVDA   184.99 (+2.22%)
NIO   21.74 (+8.43%)
BABA   96.91 (+4.85%)
AMD   101.82 (+2.80%)
MU   63.76 (+3.84%)
T   18.13 (+0.67%)
CGC   3.34 (+1.52%)
GE   78.78 (+2.13%)
F   15.73 (+1.48%)
DIS   120.52 (+7.20%)
AMC   25.41 (+7.35%)
PYPL   100.64 (+1.75%)
PFE   48.78 (-2.34%)
NFLX   249.34 (+2.14%)
S&P 500   4,244.38 (+0.81%)
DOW   33,586.05 (+0.83%)
QQQ   328.85 (+0.90%)
AAPL   170.15 (+0.54%)
MSFT   289.18 (+0.01%)
META   181.30 (+1.66%)
GOOGL   120.53 (+0.69%)
AMZN   143.27 (+0.41%)
TSLA   879.87 (-0.36%)
NVDA   184.99 (+2.22%)
NIO   21.74 (+8.43%)
BABA   96.91 (+4.85%)
AMD   101.82 (+2.80%)
MU   63.76 (+3.84%)
T   18.13 (+0.67%)
CGC   3.34 (+1.52%)
GE   78.78 (+2.13%)
F   15.73 (+1.48%)
DIS   120.52 (+7.20%)
AMC   25.41 (+7.35%)
PYPL   100.64 (+1.75%)
PFE   48.78 (-2.34%)
NFLX   249.34 (+2.14%)
NASDAQ:VBLT

Vascular Biogenics - VBLT Stock Forecast, Price & News

$0.27
+0.01 (+5.12%)
(As of 08/11/2022 10:32 AM ET)
Add
Compare
Today's Range
$0.26
$0.27
50-Day Range
$0.22
$2.10
52-Week Range
$0.21
$2.54
Volume
34,384 shs
Average Volume
8.21 million shs
Market Capitalization
$18.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.88

Vascular Biogenics MarketRank™ Forecast

Analyst Rating
Hold
2.25 Rating Score
Upside/​Downside
1,719.0% Upside
$4.88 Price Target
Short Interest
Healthy
1.35% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.33mentions of Vascular Biogenics in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.51) to ($0.54) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.74 out of 5 stars

Medical Sector

951st out of 1,112 stocks

Pharmaceutical Preparations Industry

468th out of 544 stocks

VBLT stock logo

About Vascular Biogenics (NASDAQ:VBLT) Stock

Vascular Biogenics Ltd., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. Its programs are based on its vascular targeting system, a gene-based technology targeting newly formed blood vessels; and monocyte targeting technology, an antibody-based technology that enables specifically inhibit monocyte migration for immune-inflammatory applications. The company's lead product candidate is VB-111, a gene-based biologic that is in Phase III clinical trials for the recurrent platinum-resistant ovarian cancer; and Phase II clinical trials treatment of recurrent glioblastoma and colorectal cancer, as well as has completed Phase II clinical trial for the treatment of thyroid cancer. It is also developing VB-601 for various inflammatory indications, and VB-611 for various solid tumors. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel.

Analysts Set New Price Targets

A number of equities research analysts have commented on VBLT shares. Oppenheimer cut shares of Vascular Biogenics from an "outperform" rating to a "market perform" rating in a research note on Wednesday, July 20th. StockNews.com started coverage on shares of Vascular Biogenics in a research note on Saturday. They set a "sell" rating on the stock. Chardan Capital cut shares of Vascular Biogenics from a "buy" rating to a "neutral" rating in a research note on Wednesday, July 20th. Jonestrading reiterated a "buy" rating and set a $5.00 price objective on shares of Vascular Biogenics in a research report on Friday, May 20th. Finally, HC Wainwright cut shares of Vascular Biogenics from a "buy" rating to a "neutral" rating in a research report on Wednesday, July 20th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and one has given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $4.88.

Vascular Biogenics Stock Performance

Shares of Vascular Biogenics stock traded up $0.02 on Wednesday, hitting $0.26. 4,803,664 shares of the company traded hands, compared to its average volume of 1,258,668. The stock has a market capitalization of $17.89 million, a P/E ratio of -0.56 and a beta of 0.58. Vascular Biogenics has a 52 week low of $0.21 and a 52 week high of $2.54. The business has a 50-day simple moving average of $1.20 and a 200 day simple moving average of $1.39.

Vascular Biogenics (NASDAQ:VBLT - Get Rating) last released its quarterly earnings data on Tuesday, May 17th. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.01). Vascular Biogenics had a negative net margin of 4,894.40% and a negative return on equity of 69.21%. The company had revenue of $0.11 million for the quarter, compared to the consensus estimate of $0.20 million. During the same quarter in the previous year, the business earned ($0.12) EPS. Research analysts expect that Vascular Biogenics will post -0.51 earnings per share for the current year.

Receive VBLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vascular Biogenics and its competitors with MarketBeat's FREE daily newsletter.

VBLT Stock News Headlines

Vascular Biogenics (NASDAQ:VBLT) Now Covered by StockNews.com
Vascular Biogenics Cutting About 35% of Staff >VBLT
VBL Therapeutics Announces Workforce Reduction
Vascular Biogenics (NASDAQ:VBLT) Downgraded by HC Wainwright
Vascular Biogenics Earnings Preview
Vascular Biogenics earnings: here's what Wall Street expects
See More Headlines
Receive VBLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vascular Biogenics and its competitors with MarketBeat's FREE daily newsletter.

VBLT Company Calendar

Last Earnings
5/17/2022
Today
8/11/2022
Next Earnings (Estimated)
8/15/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VBLT
Previous Symbol
NASDAQ:VBLX
Employees
41
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.88
High Stock Price Forecast
$5.50
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+1,697.6%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
4 Analysts

Profitability

Net Income
$-29,920,000.00
Net Margins
-4,894.40%
Pretax Margin
-3,703.30%

Debt

Sales & Book Value

Annual Sales
$770,000.00
Book Value
$0.73 per share

Miscellaneous

Free Float
N/A
Market Cap
$18.80 million
Optionable
Optionable
Beta
0.57

Key Executives

  • Prof. Dror Harats M.D. (Age 65)
    CEO & Director
  • Dr. Eyal Breitbart Ph.D. (Age 55)
    Sr. VP of Research & Operations
  • Dr. Naamit Sher Ph.D. (Age 68)
    Sr. VP of Drug Devel. & Regulatory Affairs
  • Dr. Erez Feige M.B.A. (Age 48)
    Ph.D., Sr. VP of Bus. Operations
  • Mr. Amos Ron (Age 67)
    Company Sec.
  • Mr. Samuel Backenroth (Age 38)
    Chief Financial Officer
  • Advocate Ayelet Horn (Age 51)
    Gen. Counsel
  • Deborah Scott
    Managing Director of Financial Communications
  • Dr. Tami Rachmilewitz M.D. (Age 52)
    Sr. VP of Clinical Devel.
  • Mr. Matthew Trudeau M.Sc.
    Chief Commercial Officer













VBLT Stock - Frequently Asked Questions

Should I buy or sell Vascular Biogenics stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vascular Biogenics in the last twelve months. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" VBLT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VBLT, but not buy additional shares or sell existing shares.
View VBLT analyst ratings
or view top-rated stocks.

What is Vascular Biogenics' stock price forecast for 2022?

4 Wall Street analysts have issued 1-year target prices for Vascular Biogenics' stock. Their VBLT share price forecasts range from $4.00 to $5.50. On average, they predict the company's stock price to reach $4.88 in the next year. This suggests a possible upside of 1,789.5% from the stock's current price.
View analysts price targets for VBLT
or view top-rated stocks among Wall Street analysts.

How have VBLT shares performed in 2022?

Vascular Biogenics' stock was trading at $1.97 at the beginning of 2022. Since then, VBLT shares have decreased by 86.9% and is now trading at $0.2580.
View the best growth stocks for 2022 here
.

Are investors shorting Vascular Biogenics?

Vascular Biogenics saw a increase in short interest in the month of July. As of July 31st, there was short interest totaling 642,600 shares, an increase of 122.0% from the July 15th total of 289,500 shares. Based on an average trading volume of 2,620,000 shares, the days-to-cover ratio is presently 0.2 days. Approximately 1.4% of the company's shares are sold short.
View Vascular Biogenics' Short Interest
.

When is Vascular Biogenics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022.
View our VBLT earnings forecast
.

How were Vascular Biogenics' earnings last quarter?

Vascular Biogenics Ltd. (NASDAQ:VBLT) issued its earnings results on Tuesday, May, 17th. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by $0.01. The biopharmaceutical company earned $0.11 million during the quarter, compared to analysts' expectations of $0.20 million. Vascular Biogenics had a negative trailing twelve-month return on equity of 69.21% and a negative net margin of 4,894.40%. During the same period last year, the business earned ($0.12) earnings per share.

What other stocks do shareholders of Vascular Biogenics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vascular Biogenics investors own include SCYNEXIS (SCYX), Matinas BioPharma (MTNB), OPKO Health (OPK), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Aeterna Zentaris (AEZS), Dynavax Technologies (DVAX), Vaxart (VXRT) and Geron (GERN).

What is Vascular Biogenics' stock symbol?

Vascular Biogenics trades on the NASDAQ under the ticker symbol "VBLT."

How do I buy shares of Vascular Biogenics?

Shares of VBLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vascular Biogenics' stock price today?

One share of VBLT stock can currently be purchased for approximately $0.26.

How much money does Vascular Biogenics make?

Vascular Biogenics (NASDAQ:VBLT) has a market capitalization of $17.89 million and generates $770,000.00 in revenue each year. The biopharmaceutical company earns $-29,920,000.00 in net income (profit) each year or ($0.46) on an earnings per share basis.

How can I contact Vascular Biogenics?

Vascular Biogenics' mailing address is 8 HASATAT STREET, MODI IN L3, 7178106. The official website for the company is www.vblrx.com. The biopharmaceutical company can be reached via phone at (728) 993-5000, via email at ir@vblrx.com, or via fax at 972-8993-5001.

This page (NASDAQ:VBLT) was last updated on 8/11/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.